Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 3/20 | 0.61 |
| ▸ | SKP1 | P63208 | 3/20 | 0.61 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | HPGDS | O60760 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048031 | 0.99 | CKS1B (0.60) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL16049430 | 0.90 | CKS1B (0.58) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL6139686 | 0.90 | HRH3 (0.60) | CKS1BSKP1SKP2MAPK8RET | |
| Lithium Ion SCHEMBL30026169 | 0.89 | CKS1B (0.57) | CKS1BSKP1SKP2MAPK8RET | |
| Lithium Ion SCHEMBL16048029 | 0.89 | CKS1B (0.57) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL6139979 | 0.86 | ALDH1A1 (0.55) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL6140015 | 0.86 | CKS1B (0.56) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL21564581 | 0.86 | CKS1B (0.61) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL530038 | 0.86 | CKS1B (0.61) | CKS1BSKP1SKP2MAPK8RET | |
| SCHEMBL7080374 | 0.86 | CKS1B (0.61) | CKS1BSKP1SKP2MAPK8RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180194763-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9951068-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2018-04-24 | — | — | US | disclosed |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-08-31 | — | — | US | disclosed |
| US-9676769-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-20160326172-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-11-10 | — | — | US | disclosed |
| US-9428498-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-6852736-B2 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-02-08 | — | — | US | disclosed |
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326172-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | CKS1B 3587/4885SKP1 2094/4885SKP2 845/4885 |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | CKS1B 2179/4885SKP1 469/4885SKP2 1195/4885 |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | CKS1B 2179/4885SKP1 469/4885SKP2 1195/4885 |
| US-20140275040-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | CKS1B 3587/4885SKP1 2094/4885SKP2 845/4885 |
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | ACE2, TMPRSS2, IL1B | CKS1B 1090/4885SKP1 1887/4885SKP2 1817/4885 |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, SSB, XDH | CKS1B 2179/4885SKP1 469/4885SKP2 1195/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | CKS1B 3330/4885SKP1 670/4885SKP2 1615/4885 |
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | CNR1, ADRB3, ADRB1 | CKS1B 1386/4885SKP1 729/4885SKP2 2027/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | CKS1B 3330/4885SKP1 670/4885SKP2 1615/4885 |
| US-20180194763-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, SSB, XDH | CKS1B 2179/4885SKP1 469/4885SKP2 1195/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | CKS1B 3388/4885SKP1 1952/4885SKP2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.